Koizumi K, Uchiyama G, Komatsu H
Department of Radiology, Yamanashi Medical University, Japan.
Ann Nucl Med. 1994 Nov;8(4):225-30. doi: 10.1007/BF03165024.
Bone scintigraphy is often performed to assess the response to systemic therapy of bone metastasis from prostate cancer. We examined the changes in bone scintigraphic findings and the agreement with AIP, AcP, or other tumor markers measured in the follow-up of patients with known bone metastasis after hormonal therapy. Out of 32 patients, 22 (69%) showed improved scintigraphic findings on the first follow-up bone scintigraphy after hormonal therapy. However, 7 out of 22 patients who showed improvement on the first follow-up scintigraphy, deteriorated thereafter. Changes in the scintigraphic findings were closely correlated with those in the measured tumor markers except for patients with small bone metastasis. Though there were no significant differences in the agreement ratios of the 6 tumor markers evaluated, AIP might be a practical and acceptable indicator. Bone X-ray findings did not change at all in almost half of the cases though the scintigraphic findings showed improvement or deterioration.
骨闪烁显像术常用于评估前列腺癌骨转移的全身治疗反应。我们在已知骨转移的患者接受激素治疗后的随访中，检查了骨闪烁显像结果的变化以及与碱性磷酸酶（AIP）、酸性磷酸酶（AcP）或其他肿瘤标志物的一致性。在32例患者中，22例（69%）在激素治疗后的首次随访骨闪烁显像中显示出显像结果改善。然而，在首次随访闪烁显像中显示改善的22例患者中，有7例随后病情恶化。除骨转移较小的患者外，闪烁显像结果的变化与所测肿瘤标志物的变化密切相关。尽管评估的6种肿瘤标志物的一致性比率没有显著差异，但AIP可能是一个实用且可接受的指标。尽管闪烁显像结果显示改善或恶化，但几乎一半的病例中骨X线检查结果完全没有变化。
